Lilly France

Founded in 2019 and headquartered in Shanghai, Ronovo Surgical is founded by industry veterans from global leaders in surgical and industrial robotics, such as Intuitive Surgical, Johnson & Johnson, Medtronic and KUKA. Aiming to transform how surgery is performed in China, Ronovo is leveraging robust R&D capabilities and strategic partnerships globally to accelerate the development of a broad portfolio of MIS and digital surgery solutions that exemplifies the core themes of simplicity, precision, and intelligence.

Sonoma Biotherapeutics is a company invloved the development of adoptive Treg therapies cell for autoimmune and degenerative diseases. Using next generation genome editing and target-specific cell therapy, Sonoma is focused on developing its best-in-class platform across the entire spectrum of Treg cell therapeutic capabilities. Founded by pioneers in Treg biology and cell therapy, the company brings together leading expertise and proprietary methodologies for the discovery and development of disease modifying and curative therapies.

Passage Bio, Inc., a genetic medicines company, focuses on developing transformative therapies for rare monogenic central nervous system (CNS) diseases. It has research, collaboration, and license agreement with the University of Pennsylvania and its gene therapy program; and The Trustees of the University of Pennsylvania for research and development collaborations, and exclusive license rights to patents for certain products and technologies. The company was founded in 2017 and is based in Philadelphia, Pennsylvania.

NuVera Medical, Inc. operates an imaging platform for cardiovascular procedures. The product uses 4D ultrasound technology to process the images. The product can be used by healthcare specialists for Intracardiac Echocardiography. NuVera Medical, Inc. was founded in 2016 and is based in Campbell, California.

Neukio Biotherapeutics is an immune cell drug developer, focusing on the research and development and industrialization of immune cell drugs, developing iPSC-CAR-NK general-purpose spot immune cell products, and is committed to providing effective therapeutic drugs for cancer patients around the world.

Passage Bio, Inc., a genetic medicines company, focuses on developing transformative therapies for rare monogenic central nervous system (CNS) diseases. It has research, collaboration, and license agreement with the University of Pennsylvania and its gene therapy program; and The Trustees of the University of Pennsylvania for research and development collaborations, and exclusive license rights to patents for certain products and technologies. The company was founded in 2017 and is based in Philadelphia, Pennsylvania.

ACEA Biosciences is a biotechnology company founded in 2002 and headquartered in San Diego, California. ACEA is a pioneer in the development and commercialization of high-performance microelectronic systems for cell-based assays. ACEA has a world-class manufacturing operation centered in Hangzhou, Zhejiang Province, China. The Life Technology Business Unit developed ACEA’s proprietary real-time, label-free cell-based assay technology and launched the first product in 2004. The technology has been marketed globally under the xCELLigence brand. There are over 800 customers worldwide, and over 350 peer-reviewed publications using the xCELLigence technology. The newly launched iCELLigence instrument with wireless connectivity makes this innovative technology affordable to all users. In addition to the Life Technology Business Unit, ACEA also has a Therapeutics Business Unit which was launched in 2005. ACEA Therapeutics is focused on oncology drug discovery and development, leveraging the platform biosensor technology and proprietary small molecule library (> 1 million compounds) to bring novel therapeutics into the clinic. ACEA currently has one program in phase II clinical trials in China and numerous early clinical and preclinical leads. With its international reach, ACEA Biosciences continues to work closely with scientists throughout the world to bring innovation to the R&D and health care industries.

Nuohui Health is an innovative bio-tech company focusing on early screening and genetic testing services for high-incidence cancer homes. Nuohui Health is committed to reducing the morbidity and mortality of cancer through biotechnological means. It first proposed the slogan of early cancer screening and is committed to promoting early cancer screening into thousands of households so that the public can enjoy convenient and efficient health services .

Transcenta Holding Ltd., a biotherapeutics company, engages in the research and development and manufacturing of antibody-based therapeutics. The company also offers clinical researches and trial services. Transcenta Holding Ltd. was founded in 2019 and is based in Suzhou, China. It has additional centers in Shanghai, Hangzhou, and Beijing, China; Waltham, Massachusetts; and Princeton, New Jersey.

Tianjin CanSino Biotech Inc. is an emerging biotechnology company dedicated to vaccine research, development and commercialization. We seek to address the pressing unmet medical needs by developing and marketing leading-edge, high quality vaccines for China and other emerging markets at affordable prices.

Established in 2008, Geneseeq is an industry leader in Next-Generation Sequencing (NGS) fully committed to the research and clinical translation of NGS Genetic Sequencing in the field of personalized medicine. Geneseeq’s world-leading laboratories have successfully passed China’s National Center of Clinical Laboratories(NCCL) External Quality Assessment(EQA), College of American Pathologists(CAP) PT, European Molecular Genetics Quality Network(EMQN) PT, and received 3rd party medical laboratory and clinical PCR amplification laboratory qualifications.

IMPACT Therapeutics is dedicated to the development of similar drugs to treat cancer have independent intellectual property rights and other diseases of the best (best-in-class) of new drugs and its commercialization. The company's senior management team of experienced and professional background complementary and have accumulated more than four decades of experience in drug development and management. General Manager and Chief Scientific Officer Field are an expert in pharmacology and biology.

Transcenta Holding Ltd., a biotherapeutics company, engages in the research and development and manufacturing of antibody-based therapeutics. The company also offers clinical researches and trial services. Transcenta Holding Ltd. was founded in 2019 and is based in Suzhou, China. It has additional centers in Shanghai, Hangzhou, and Beijing, China; Waltham, Massachusetts; and Princeton, New Jersey.

KSQ Therapeutics is pioneering High-Confidence Drug Development: a fundamentally new approach to R&D where the majority of the de-risking work is done prior to the generation of therapeutic drug candidates. Powered by our proprietary CRISPRomics™ drug discovery engine, their team has elucidated the function that each human gene plays in multiple diseases, providing a unique and more comprehensive understanding of disease biology. The quality of these insights enables their scientists to rapidly identify and validate high-confidence, patient-tailored, novel drug targets and then focus their collective efforts on the development of medicines with the greatest potential to impact the lives of patients. KSQ has initiated a pipeline of preclinical discovery programs and was founded in 2015.

Synthekine is an engineered cytokine therapeutics company developing disease-optimized treatments. The company uses immunological insights to guide targeted protein engineering to generate transformative medicines for cancer and autoimmune disorders. Using the principles of cytokine partial agonism and immunological specificity, Synthekine designs differentiated therapeutics to be both safe and efficacious. Its lead programs have shown promising efficacy and tolerability in preclinical studies, and it is developing additional cytokine partial agonists that selectively modulate key pathways of the immune system.

Fountain Medical Development Ltd., a contract research organization, provides ICH GCP compliant clinical research services for the multinational clients in China and the United States. It offers consulting, project management, regulatory affairs, clinical operations, central laboratory services, site management, biometrics, and clinical trial designs, as well as AE/SAE collection, review, assessment and reporting services, data and safety monitoring board handling, and signal detection services. The company is based in Beijing, China.

Singleron Biotechnologies is a developer and provider of clinical diagnosis, health management and drug development products and services. The company is dedicated to applying single cell analysis techniques and has obtained a world wide exclusive IP license from Yale University for its uniquely designed microfluidic single cell processing device, and has developed the innovative SCOPE single-cell pre-sequencing preparation system based on this microfluidic device.

MabSpace Biosciences, is a biotech company focused on discovery and development of innovative antibody based therapeutics for cancer and fibrotic diseases. It was founded in 2013 by indrustrial veterans and is located in Biobay Suzhou, an emerging bitech incubator in China. MabSpace employes its proprietary platform technology, immune tolerance breaking technology (IMBT), to generate lead antibodies with diverse epitopes. MabSpace has established multiple antibody discovery and co-development partnerships based on this technology. MabSpace raised 15 million USD from Lilly Asia Ventures in 2015 to advance its lead antibody program, a potentially best-in-class anti-PD-L1 antibody with unique pH-dependent binding and recycling property and significantly improved efficacy in animal models. It has also built a panel of 2nd generation immuno-oncology antibodies targeting different components of the tumor microenvironment,which enables the testing of combination therapeutic interventions with its PD-L1 antibody.

Terns Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops molecularly targeted, oral, small-molecule drugs to treat cancer and liver diseases. Its products includes TERN-101, a potent non-bile acid farnesoid X receptor agonist and TERN-201, a semicarbazide-sensitive amine oxidase inhibitor. The company was founded in 2017 and is based in Foster City, California with additional offices in Shanghai, China.

Hangzhou Just Biotherapeutics, Ltd., also known as Just China, develops antibody and recombinant protein bio-therapeutics. The company was founded in 2016 and is based in Hangzhou, China. Hangzhou Just Biotherapeutics, Ltd. operates as a subsidiary of Just Biotherapeutics, Inc. As of January 2, 2019, Hangzhou Just Biotherapeutics, Ltd. operates as a subsidiary of MabSpace Biosciences Co., Ltd..

dMed Company Limited, also known as, dMed Biopharmaceutical Co., Ltd. operates as clinical contract research organization providing services for development of medicines and medical devices. The company offer services, including consulting, clinical operations, biostatistics & programming, data management, pharmacovigilance, clinical science & medical affairs, quality assurance, and regulatory affairs & Strategy. It serves biopharmaceutical and medical device companies. dMed Company Limited was founded in 2016 and is based in Shanghai, China.

Turning Point Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in designing and developing novel small molecule targeted oncology therapies. It develops a pipeline of tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in TKI-naïve and TKI-pretreated patients. The company’s lead drug candidate repotrectinib is being evaluated in an ongoing Phase I/II trial called TRIDENT-1 for the treatment of patients with ROS1+ advanced non-small-cell lung cancer (NSCLC) and patients with ROS1+, NTRK+, or ALK+ advanced solid tumors. Its pipeline also includes multi-targeted drug candidates TPX-0046, a RET/SRC inhibitor; TPX-0022, a MET/CSF1R/SRC inhibitor; and TPX-0131, a preclinical ALK inhibitor. The company was founded in 2013 and is headquartered in San Diego, California.

InventisBio is a biotech company whose product pipeline includes small molecule drug candidates for targeted therapies in lung cancer, breast cancer and gout. The company is also actively developing drugs that can be combined with other immune-oncology targeted therapies, such as PD-1 antibody, for various cancer indications. The company is co-founded by Dr. Yaolin Wang and other scientists who have previously worked at Merck and Schering-Plough, leading various drug discovery projects in oncology, metabolic and infectious disease areas.

Novlead Biotech contributes to a safer and healthier human well-being through our technological innovations.

Veritas Genetics is a provider of a genetic testing platform intended to empower people to live healthier and longer. The company's genetic technology can detect a wider range of variations in a gene than are typically found in next-generation sequencing and offers a screening test for hereditary breast and ovarian cancer risk, enabling clinical researchers and physicians in order to make informed decisions.

Positive Sequence Biology is a biotech company with new gene system-based editing, focused on biotech innovation & breakthrough therapies.

Abbisko Therapeutics Co. Ltd. discovers, develop, and manufactures immuno-oncology therapies. It offers ABSK011 and ABSK021, which are molecule inhibitors for treating hepatocellular carcinoma; and CSF1R for the treatment of solid tumors. The company also develops therapeutics for the treatment of cancer, tumor, and diabetes, metabolic diseases, liver diseases, viral infections and CNS diseases. The company was founded in 2016 and is based in is based in Shanghai, China.

Rgenta Therapeutics develops a pipeline of oral, small-molecule RNA-targeting medicines with an initial focus on oncology. Its proprietary platform mines the massive genomics data to identify targetable RNA processing events and design small-molecule glue to modulate the interactions among the spliceosome, regulatory proteins, and RNAs. Its lead programs and unique approach are unlocking the therapeutic potential of historically undruggable targets in human diseases. It was founded in 2018 and is headquartered in Cambridge, Massachusetts.

ProfoundBio is an oncology biotherapeutics company focused on the development of novel antibody-based therapeutics with curative potential for patients with cancer.

Alebund Pharmaceuticals is a biopharmaceutical company dedicated to developing innovative therapies for the treatment of renal diseases and related chronic conditions.

EdiGene is dedicated to the development of genome editing technology for human health. Genome editing technology enables the targeted modification of genetic information in human cells, including gene knockout, knock-in and targeted mutations. They aim at providing the high quality products and services for the patients, the pharmaceutical industry, and the scientific research community with the most advanced genome editing technology.EdiGene innovates and applies genome editing technology to developing human therapeutic products. Their therapeutic approach is to treat diseases at the molecular level, making gene therapy safer and more effective.

Transcenta Holding Ltd., a biotherapeutics company, engages in the research and development and manufacturing of antibody-based therapeutics. The company also offers clinical researches and trial services. Transcenta Holding Ltd. was founded in 2019 and is based in Suzhou, China. It has additional centers in Shanghai, Hangzhou, and Beijing, China; Waltham, Massachusetts; and Princeton, New Jersey.

SciNeuro Pharmaceuticals develops medicines for patients with central nervous system (CNS) diseases. The company is based in Shanghai, China.

Inhibrx is a clinical-stage biotechnology company focused on developing a broad pipeline of novel biologic therapeutic candidates. Inhibrx utilizes diverse methods of protein engineering to address the specific requirements of complex target and disease biology, including its proprietary sdAb platform. The Inhibrx pipeline is focused on oncology, orphan diseases and infectious diseases. Inhibrx has collaborations with Celgene and bluebird bio and has received awards from several granting agencies, including NIH, NIAID and CARB-X.

Scivita Medical is a high-tech enterprise engaged in the field of optical diagnosis and treatment, multidimensional images development, high-performance materials research and precision manufacturing with minimally invasive medical treatment. Scivita Medical's product covers both flexible endoscopy and rigid endoscopy, and has unique advantages in the research and commercialization of all cutting-edge technologies in the field of medical endoscopes. It has ultra-high-definition visualization technology (such as 4K UHD visualization), 3D visualization technology, special light visualization technology (such as fluorescence visualization), ultra-fine endoscopic visualization technology, single-use technology, etc.

MicroTech Medical founded in January, 2011 in Hangzhou Future Technical City, which is the Industrial Garden for High-level Overseas Talents in Zhejiang Province, recieved capital from Eli Lilly and Company. They devote to innovate and manufacture high-tech and more affordable medical devices related to Diabetes Care.

Sonoma Biotherapeutics is a company invloved the development of adoptive Treg therapies cell for autoimmune and degenerative diseases. Using next generation genome editing and target-specific cell therapy, Sonoma is focused on developing its best-in-class platform across the entire spectrum of Treg cell therapeutic capabilities. Founded by pioneers in Treg biology and cell therapy, the company brings together leading expertise and proprietary methodologies for the discovery and development of disease modifying and curative therapies.

Just Evotec Biologics was founded in 2014 and acquired by Evotec in 2019. The company has an intense focus on the design of innovative and integrated technologies to accelerate the development of biotherapeutics and reduce their manufacturing cost. Core strengths include antibody discovery, molecular design, process and product design and manufacturing plant design.

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in phase II clinical trial for the treatment of frontotemporal dementia disease; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer’s and Parkinson’s diseases. The company also offers AL002 and AL003, which are in phase 1b clinical trial for the treatment of Alzheimer’s disease. In addition, it has 10 programs under research and development stage. The company has a collaboration agreement with Adimab, LLC for the research and development of antibodies. Alector, Inc. was founded in 2013 and is headquartered in South San Francisco, California.

Singleron Biotechnologies is a developer and provider of clinical diagnosis, health management and drug development products and services. The company is dedicated to applying single cell analysis techniques and has obtained a world wide exclusive IP license from Yale University for its uniquely designed microfluidic single cell processing device, and has developed the innovative SCOPE single-cell pre-sequencing preparation system based on this microfluidic device.

MabSpace Biosciences, is a biotech company focused on discovery and development of innovative antibody based therapeutics for cancer and fibrotic diseases. It was founded in 2013 by indrustrial veterans and is located in Biobay Suzhou, an emerging bitech incubator in China. MabSpace employes its proprietary platform technology, immune tolerance breaking technology (IMBT), to generate lead antibodies with diverse epitopes. MabSpace has established multiple antibody discovery and co-development partnerships based on this technology. MabSpace raised 15 million USD from Lilly Asia Ventures in 2015 to advance its lead antibody program, a potentially best-in-class anti-PD-L1 antibody with unique pH-dependent binding and recycling property and significantly improved efficacy in animal models. It has also built a panel of 2nd generation immuno-oncology antibodies targeting different components of the tumor microenvironment,which enables the testing of combination therapeutic interventions with its PD-L1 antibody.

EdiGene is dedicated to the development of genome editing technology for human health. Genome editing technology enables the targeted modification of genetic information in human cells, including gene knockout, knock-in and targeted mutations. They aim at providing the high quality products and services for the patients, the pharmaceutical industry, and the scientific research community with the most advanced genome editing technology.EdiGene innovates and applies genome editing technology to developing human therapeutic products. Their therapeutic approach is to treat diseases at the molecular level, making gene therapy safer and more effective.

Tmunity Therapeutics, Inc., a bio-therapeutics company, develops immunotherapies for cancer, infectious disease, and autoimmune disease treatment. The company was incorporated in 2015 and is based in Philadelphia, Pennsylvania.

Harpoon Therapeutics is a clinical-stage immunotherapy company developing a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient’s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. Using its proprietary Tri-specific T cell Activating Construct (TriTAC), platform, Harpoon is developing a pipeline of novel T cell engagers, or TriTACs, initially focused on the treatment of solid tumors and hematologic malignancies. Harpoon's first drug candidate, HPN424, is currently in Phase 1 clinical trial as a treatment for prostate cancer.

Elpiscience Biopharmaceuticals Co., Ltd. operates as an immunology company that develops immunotherapies to treat cancer. The company is based in Pudong, China with an additional office in Suzhou, China.

dMed Company Limited, also known as, dMed Biopharmaceutical Co., Ltd. operates as clinical contract research organization providing services for development of medicines and medical devices. The company offer services, including consulting, clinical operations, biostatistics & programming, data management, pharmacovigilance, clinical science & medical affairs, quality assurance, and regulatory affairs & Strategy. It serves biopharmaceutical and medical device companies. dMed Company Limited was founded in 2016 and is based in Shanghai, China.

Sansure Biotech Inc. develops and sells upstream nucleic acid extraction kits, real time PCR diagnostic and research kits, and fluorescence systems in China and internationally. The company offers novel coronavirus nucleic acid diagnostic kits; viral hepatitis and AIDS, blood screening, and extraction kits; cancer-related biomarkers; and kits for respiratory tract diseases, STDs, digestive tract diseases, prenatal and postnatal care, and genetic diseases, as well as instruments and other consumables. It serves hospitals and laboratories. The company was founded in 2008 and is based in Changsha, China.

Tripod is a Contract Research Organization in the biopharmaceutical space that provides preclinical research services for global pharma companies, R&D enterprises and institutes, and medical device developers. Tripod (TPR) is dedicated to nonclinical research (drug safety evaluation) for the candidates of new chemical entity (NCE), food additives, biologics，pesticides，veterinary drugs, and new cosmetics.

Just Evotec Biologics was founded in 2014 and acquired by Evotec in 2019. The company has an intense focus on the design of innovative and integrated technologies to accelerate the development of biotherapeutics and reduce their manufacturing cost. Core strengths include antibody discovery, molecular design, process and product design and manufacturing plant design.

Singlera Genomics is a fast growing company focusing on non-invasive genetic testing. Singlera’s main products and services include tumor diagnosis and personalized treatment, non-invasive prenatal diagnosis, pre-implantation genetic screening, and customized scientific research services. Singlera is dedicated to the development of precision medicine, striving to help the patients through early, accurate and informative diagnoses.

Magnolia Neurosciences aims to discover and develop proprietary, selective, and drug-like small molecule therapeutics for the prevention of neuronal cell death, thereby providing novel treatment options for patients suffering from neurodegeneration and related conditions. Magnolia Neurosciences Corporation, created to pursue technologies developed at The University of Texas MD Anderson Cancer Center’s Therapeutics Discovery Division and the Neurodegeneration Consortium (NDC), is a New York-based Accelerator Life Science Partner portfolio company.

Abbisko Therapeutics Co. Ltd. discovers, develop, and manufactures immuno-oncology therapies. It offers ABSK011 and ABSK021, which are molecule inhibitors for treating hepatocellular carcinoma; and CSF1R for the treatment of solid tumors. The company also develops therapeutics for the treatment of cancer, tumor, and diabetes, metabolic diseases, liver diseases, viral infections and CNS diseases. The company was founded in 2016 and is based in is based in Shanghai, China.

Veritas Genetics is a provider of a genetic testing platform intended to empower people to live healthier and longer. The company's genetic technology can detect a wider range of variations in a gene than are typically found in next-generation sequencing and offers a screening test for hereditary breast and ovarian cancer risk, enabling clinical researchers and physicians in order to make informed decisions.

Neukio Biotherapeutics is an immune cell drug developer, focusing on the research and development and industrialization of immune cell drugs, developing iPSC-CAR-NK general-purpose spot immune cell products, and is committed to providing effective therapeutic drugs for cancer patients around the world.

EdiGene is dedicated to the development of genome editing technology for human health. Genome editing technology enables the targeted modification of genetic information in human cells, including gene knockout, knock-in and targeted mutations. They aim at providing the high quality products and services for the patients, the pharmaceutical industry, and the scientific research community with the most advanced genome editing technology.EdiGene innovates and applies genome editing technology to developing human therapeutic products. Their therapeutic approach is to treat diseases at the molecular level, making gene therapy safer and more effective.

ReadCoor, Inc. develops and commercializes a panomic spatial sequencing platform for researchers, clinicians, pharmaceutical and diagnostics companies, and patients worldwide. It offers FISSEQ, a platform that enables integration of high throughput sequencing, morphometric analysis, cellular location, and three-dimensional spatial imaging. The company’s platform also enables researchers to perform RNA-Seq while preserving sample morphology and simultaneously providing cellular location and spatial image data. ReadCoor, Inc. was incorporated in 2016 and is based in Cambridge, Massachusetts. As of October 13, 2020, ReadCoor, Inc. operates as a subsidiary of 10x Genomics, Inc.

KSQ Therapeutics is pioneering High-Confidence Drug Development: a fundamentally new approach to R&D where the majority of the de-risking work is done prior to the generation of therapeutic drug candidates. Powered by our proprietary CRISPRomics™ drug discovery engine, their team has elucidated the function that each human gene plays in multiple diseases, providing a unique and more comprehensive understanding of disease biology. The quality of these insights enables their scientists to rapidly identify and validate high-confidence, patient-tailored, novel drug targets and then focus their collective efforts on the development of medicines with the greatest potential to impact the lives of patients. KSQ has initiated a pipeline of preclinical discovery programs and was founded in 2015.

ADARx Pharmaceuticals is a genetic medicine company focusing on the base editing of mRNA transcripts. It discovers and develops innovative therapeutics that can utilize a family of endogenous enzymes called adenosine deaminase acting on RNA (ADAR) to precise target and correct single point mutations on an mRNA, thus the production of desired and functional protein is restored. It was founded in 2019 and is headquartered in San Diego, California.

NextCure is a biopharmaceutical company focused on discovering and developing next generation immuno-oncology-based drugs. The Company is applying its proprietary platforms and know-how to identify novel and biologically relevant targets and develop first-in-class immunotherapy products.

Guangzhou Lupeng Pharmaceutical Co., Ltd. is mainly engaged in the research and development of drugs for the treatment of tumors, hepatitis B, autoimmunity and other major diseases. The company was founded in 2018 and is based in Guangzhou, China with additional offices in Silicon Valley, San Francisco and United States.

ImmuneOnco Biopharmaceuticals (Shanghai) Co.,Ltd. develops and commercializes novel cancer immunotherapy products. The company designs platforms to reverse cancer cell-induced immune inhibition and to eradicate cancer cells. It offers platforms harnessing two types of innate immune cells, macrophages and natural killer (NK) cells to fulfill the cancer-killing task. The company’s platforms include Target-Activated NK (TANK™) Cell Therapy, PD-1/PD-L1 antibody blockade assay platform, and Activating Macrophages. The company was founded in 2015 and is headquartered in Shanghai, China.

ArriVent is dedicated to accelerating the global development of innovative biopharmaceutical products.

Tmunity Therapeutics, Inc., a bio-therapeutics company, develops immunotherapies for cancer, infectious disease, and autoimmune disease treatment. The company was incorporated in 2015 and is based in Philadelphia, Pennsylvania.

Alebund Pharmaceuticals is a biopharmaceutical company dedicated to developing innovative therapies for the treatment of renal diseases and related chronic conditions.

Zentera Therapeutics is a biopharmaceutical company.

Alebund Pharmaceuticals is a biopharmaceutical company dedicated to developing innovative therapies for the treatment of renal diseases and related chronic conditions.

Dizal Pharmaceutical is a research-based biotechnology company dedicated to the discovery, development, and commercialization of first-in-class/best-in-class medicines.

Hangzhou Just Biotherapeutics, Ltd., also known as Just China, develops antibody and recombinant protein bio-therapeutics. The company was founded in 2016 and is based in Hangzhou, China. Hangzhou Just Biotherapeutics, Ltd. operates as a subsidiary of Just Biotherapeutics, Inc. As of January 2, 2019, Hangzhou Just Biotherapeutics, Ltd. operates as a subsidiary of MabSpace Biosciences Co., Ltd..

Ionova Life Science Co., Ltd. operates as a biotechnology company. The company engages in discovery and development of novel medicine for cancer treatment. It focuses on oncology, including immune-oncology and target delivery. The company uses its in-house build discovery platform for the development purpose. Ionova Life Science Co., Ltd. was founded in 2016 and is based in Shenzhen, China with additional offices in Hong Kong, Macao and Greater Bay Area.

NuVera Medical, Inc. operates an imaging platform for cardiovascular procedures. The product uses 4D ultrasound technology to process the images. The product can be used by healthcare specialists for Intracardiac Echocardiography. NuVera Medical, Inc. was founded in 2016 and is based in Campbell, California.

Nuohui Health is an innovative bio-tech company focusing on early screening and genetic testing services for high-incidence cancer homes. Nuohui Health is committed to reducing the morbidity and mortality of cancer through biotechnological means. It first proposed the slogan of early cancer screening and is committed to promoting early cancer screening into thousands of households so that the public can enjoy convenient and efficient health services .

Gracell Biotechnologies is a developer of cancer immune therapy designed to treat cancer. The company's therapy offers cellular therapeutics for the patients suffered from hematological malignancy, solid tumor or degenerative disease, enabling healthcare providers to cure their patients and improve their lives.

Shanghai Xihua Scientific Technology Services Co., Ltd. is engaged in clinical research services on drugs based on biological analysis. The firm is headquartered in Shanghai, China.

Elpiscience Biopharmaceuticals Co., Ltd. operates as an immunology company that develops immunotherapies to treat cancer. The company is based in Pudong, China with an additional office in Suzhou, China.

Suzhou Connect Biopharmaceuticals, Ltd., a clinical-stage company, discovers and develops novel medicines for the treatment of autoimmune diseases and inflammation. Its products in pipeline includes CBP-307, an orally-active, second-generation S1P1 agonist for the treatment of a range of autoimmune diseases, including inflammatory bowel disease, graft-versus-host disease, psoriasis, and multiple sclerosis; CBP-174 for allergic rhinitis and atopic dermatitis; and CBP-201, a novel monoclonal antibody for the treatment of atopic dermatitis, asthma, and other types of allergic inflammation. The company is headquartered in Taicang, China with operations in Melbourne and San Diego.

InventisBio is a biotech company whose product pipeline includes small molecule drug candidates for targeted therapies in lung cancer, breast cancer and gout. The company is also actively developing drugs that can be combined with other immune-oncology targeted therapies, such as PD-1 antibody, for various cancer indications. The company is co-founded by Dr. Yaolin Wang and other scientists who have previously worked at Merck and Schering-Plough, leading various drug discovery projects in oncology, metabolic and infectious disease areas.

IMPACT Therapeutics is dedicated to the development of similar drugs to treat cancer have independent intellectual property rights and other diseases of the best (best-in-class) of new drugs and its commercialization. The company's senior management team of experienced and professional background complementary and have accumulated more than four decades of experience in drug development and management. General Manager and Chief Scientific Officer Field are an expert in pharmacology and biology.

Hangzhou Just Biotherapeutics, Ltd., also known as Just China, develops antibody and recombinant protein bio-therapeutics. The company was founded in 2016 and is based in Hangzhou, China. Hangzhou Just Biotherapeutics, Ltd. operates as a subsidiary of Just Biotherapeutics, Inc. As of January 2, 2019, Hangzhou Just Biotherapeutics, Ltd. operates as a subsidiary of MabSpace Biosciences Co., Ltd..

Turning Point Therapeutics, Inc. is a clinical-stage structure-based drug design company for the discovery and development of precision medicines for cancer and other diseases. We are focusing on the design of novel chemical identities for established oncogene drivers with secondary resistant mutations, newly identified disease-driven targets, and potential targets regulating tumor microenvironment and tumor immunity.

Hangzhou Just Biotherapeutics, Ltd., also known as Just China, develops antibody and recombinant protein bio-therapeutics. The company was founded in 2016 and is based in Hangzhou, China. Hangzhou Just Biotherapeutics, Ltd. operates as a subsidiary of Just Biotherapeutics, Inc. As of January 2, 2019, Hangzhou Just Biotherapeutics, Ltd. operates as a subsidiary of MabSpace Biosciences Co., Ltd..

IMPACT Therapeutics is dedicated to the development of similar drugs to treat cancer have independent intellectual property rights and other diseases of the best (best-in-class) of new drugs and its commercialization. The company's senior management team of experienced and professional background complementary and have accumulated more than four decades of experience in drug development and management. General Manager and Chief Scientific Officer Field are an expert in pharmacology and biology.

Dizal (Jiangsu) Pharmaceutical Co., Limited discovers, develops, and commercializes medicines in the areas of oncology, cardiovascular and metabolic diseases, and respiratory. The company was founded in 2017 and is based in China. Dizal (Jiangsu) Pharmaceutical Co., Limited operates as a subsidiary of AstraZeneca PLC.

EdiGene is dedicated to the development of genome editing technology for human health. Genome editing technology enables the targeted modification of genetic information in human cells, including gene knockout, knock-in and targeted mutations. They aim at providing the high quality products and services for the patients, the pharmaceutical industry, and the scientific research community with the most advanced genome editing technology.EdiGene innovates and applies genome editing technology to developing human therapeutic products. Their therapeutic approach is to treat diseases at the molecular level, making gene therapy safer and more effective.

NextCure is a biopharmaceutical company focused on discovering and developing next generation immuno-oncology-based drugs. The Company is applying its proprietary platforms and know-how to identify novel and biologically relevant targets and develop first-in-class immunotherapy products.

Transcenta Holding Ltd., a biotherapeutics company, engages in the research and development and manufacturing of antibody-based therapeutics. The company also offers clinical researches and trial services. Transcenta Holding Ltd. was founded in 2019 and is based in Suzhou, China. It has additional centers in Shanghai, Hangzhou, and Beijing, China; Waltham, Massachusetts; and Princeton, New Jersey.

Legend Biotech is a biopharmaceutical company bringing impactful innovations in cell therapy, and accelerating the science. They are committed to improving the lives of patients worldwide. They are also steadfast in their goal to develop innovative cellular therapies that bring us closer to a cure. It develops cell therapies from discovery through commercialization.

Singlera Genomics is a fast growing company focusing on non-invasive genetic testing. Singlera’s main products and services include tumor diagnosis and personalized treatment, non-invasive prenatal diagnosis, pre-implantation genetic screening, and customized scientific research services. Singlera is dedicated to the development of precision medicine, striving to help the patients through early, accurate and informative diagnoses.

Abbisko Therapeutics Co. Ltd. discovers, develop, and manufactures immuno-oncology therapies. It offers ABSK011 and ABSK021, which are molecule inhibitors for treating hepatocellular carcinoma; and CSF1R for the treatment of solid tumors. The company also develops therapeutics for the treatment of cancer, tumor, and diabetes, metabolic diseases, liver diseases, viral infections and CNS diseases. The company was founded in 2016 and is based in is based in Shanghai, China.

360 Health provide health care and life science services to clients in China.

Turning Point Therapeutics, Inc. is a clinical-stage structure-based drug design company for the discovery and development of precision medicines for cancer and other diseases. We are focusing on the design of novel chemical identities for established oncogene drivers with secondary resistant mutations, newly identified disease-driven targets, and potential targets regulating tumor microenvironment and tumor immunity.

Comanche Biopharma is a biopharmaceutical company that develops siRNA therapy for the treatment of preeclampsia.